UnknownPhase 2NCT00866762
A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Copenhagen University Hospital at Herlev
- Principal Investigator
- Hans C Hasselbalch, MDDepartment of Hematology, Copenhagen University Hospital Herlev
- Intervention
- HDAC inhibitor (MK-0683)(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2012
Study locations (16)
- Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
- Esberg Hospital, Esbjerg, Denmark
- Herlev Hospital, Herlev, Denmark
- Odense University Hospital, Odense, Denmark
- Roskilde Hospital, Roskilde, Denmark
- Regional Hospital Viborg, Viborg, Denmark
- VU University Medical Centre, Amsterdam, Netherlands
- University Hospital Orebro, Örebro, Sweden
- Stockholm South General Hospital (Sodersjukhuset), Stockholm, Sweden
- Karolinska University Hospital Huddinge, Stockholm, Sweden
- Sahlgrenska University Hospital & Uddevalla Hospital, Uddevalla, Sweden
- Uppsala University Hospital, Uppsala, Sweden
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
- Cardiff University, Cardiff, United Kingdom
- Russell's Hall Hospital, Dudley, United Kingdom
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00866762 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07340138Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With MyelofibrosisNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT07357727A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.